Tortugas Neuroscience’s schizophrenia drug from Hansoh Pharma has proven its worth in a phase 2b study, validating the ...

One year on from a mixed phase 3 readout, Roche has shared updated data from eye disease trials that could support FDA ...

Merck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led ...

Bristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth. | Bristol Myers Squibb has reported phase 3 wins in a ...

Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug ...

As a notorious night owl, it was already very early in the morning of October 5 when Karl Deisseroth, M.D., Ph.D., finally ...

GSK has joined Chai Discovery’s growing roster of Big Pharma clients, signing up to access protein-folding and design models.

Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...

Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...

Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing ...

Japan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders led by ...

Zealand Pharma has reported more phase 2 data on its Roche-partnered amylin analog, linking the drug candidate to competitive ...